The Italian Observational Study on Severe Osteoporosis (ISSO): 24-month results on incidence of fractures and adherence to treatment

被引:0
|
作者
Idolazzi, L. [1 ]
Maugeri, D. [2 ]
Monti, S. [3 ]
Massarotti, M. [4 ]
Osella, G. [5 ]
Barbagallo, M. [6 ]
Del Fiacco, R. [7 ]
Silvestri, S. [7 ]
机构
[1] Univ Verona, Dept Med, Lilly Rheumatol Unit, I-37100 Verona, Italy
[2] Univ Catania, Cannizzaro Hosp, Geriatr Unit, Catania, Italy
[3] Univ Roma La Sapienza, St Andrea Hosp, Dept Endocrinol, Rome, Italy
[4] Humanitas Res Hosp, Div Rheumatol & Clin Immunol, Rozzano, Italy
[5] Univ San Luigi Gonzaga, Azienda Osped, Med Interna, Orbassano, Italy
[6] Univ Palermo, Dept Internal Med & Geriatr DIBIMIS, Geriatr Unit, I-90133 Palermo, Italy
[7] Lilly Italia, Dept Med, Sesto Fiorentino, Italy
关键词
spine; spinal fractures; observational study; teriparatide; parathyroid hormone; osteoporosis; fractures; osteoporosis therapy; BONE-MINERAL DENSITY; POSTMENOPAUSAL WOMEN; NONVERTEBRAL FRACTURES; VERTEBRAL FRACTURE; RISK; TRIAL; THERAPY;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective To estimate the proportion of patients with very severe osteoporosis (those covered by the reimbursement criteria of the Italian National Health Service) experiencing new vertebral and non-vertebral fragility fractures in the first 24 months of a new anti-osteoporosis treatment. Methods Prospective observational study in men and post-menopausal women (aged > 21 years) initiating anti-osteoporosis treatment for very severe osteoporosis. Eligibility was based on teriparatide (TPD) reimbursement criteria in Italy: incident of vertebral or hip fracture during anti-resorptive treatment (minimum 1 year), or at least three prevalent severe vertebral fractures, or two prevalent severe vertebral fractures and a historical proximal hip fracture. Incidence of new clinical vertebral and non-vertebral fractures was documented by original x-rays and/or radiological reports, and a post-hoc analysis compared data from the TPD monotherapy population versus the total treated group. Results Overall, 767 patients (mean age 72.8 years, 90.7% women) were enrolled in the study, of whom 628, 538, 419 and 424 attended visits at 6, 12, 18 and 24 months, respectively. The most commonly prescribed therapy was TPD (single-agent; 64.5%), then bisphosphonates and other anti-resorptives (33.3%). A combination of different oral treatments was given to 22.5% of the patients. Overall treatment adherence at 24 months was 65.7%. In a post-hoc analysis, the overall incidence of new clinical vertebral and non-vertebral fractures in the total treated population was, respectively, 4.7% and 2.3% in the first 6 months; 1.8% and 1.6% in the 6-12 month period; 2.9% and 1.4% in the 12-18 month period; and 2.2% and 1.0% in the 18-24 month period. Conclusion In patients with very severe osteoporosis, the risk of new vertebral and non-vertebral fractures declined after the first 6 months and remained low throughout the study.
引用
收藏
页码:247 / 253
页数:7
相关论文
共 50 条
  • [31] Effects of teriparatide on bone mineral density and bone turnover markers in Japanese subjects with osteoporosis at high risk of fracture in a 24-month clinical study: 12-Month, randomized, placebo-controlled, double-blind and 12-month open-label phases
    Miyauchi, Akimitsu
    Matsumoto, Toshio
    Sugimoto, Toshitsugu
    Tsujimoto, Mika
    Warner, Margaret R.
    Nakamura, Toshitaka
    BONE, 2010, 47 (03) : 493 - 502
  • [32] Real-World Management of Macular Edema Secondary to Retinal Vein Occlusion with Intravitreal Aflibercept: 24-month Results from the AURIGA Observational Study
    Audrey Giocanti-Aurégan
    Simone Donati
    Hans Hoerauf
    Helmut Allmeier
    Kay D. Rittenhouse
    Tobias Machewitz
    Chang-Hao Yang
    Ophthalmology and Therapy, 2024, 13 : 179 - 203
  • [33] Effects of teriparatide in postmenopausal women with osteoporosis pre-treated with bisphosphonates: 36-month results from the European Forsteo Observational Study
    Jakob, F.
    Oertel, H.
    Langdahl, B.
    Ljunggren, O.
    Barrett, A.
    Karras, D.
    Walsh, J. B.
    Fahrleitner-Pammer, A.
    Rajzbaum, G.
    Barker, C.
    Lems, W. F.
    Marin, F.
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2012, 166 (01) : 87 - 97
  • [34] Evaluation of belimumab treatment in patients with systemic lupus erythematosus in a clinical practice setting: Results from a 24-month OBSErve study in Argentina
    Babini, A.
    Cappuccio, A. M.
    Caprarulo, C.
    Casado, G.
    Eimon, A.
    Figueredo, H.
    Garcia, M. A.
    Magri, S.
    Mannucci, P.
    Perez Rodriguez, S.
    Pons-Estel, B. A.
    Velozo, E. J.
    Iglesias-Rodriguez, M.
    Streger, G.
    LUPUS, 2020, 29 (11) : 1385 - 1396
  • [35] Approach in aromatase inhibitors - induced osteoporosis: results from an Italian multicenter observational study
    Migliaccio, Silvia
    de Sire, Alessandro
    Marocco, Chiara
    Fornari, Rachele
    Paoletta, Marco
    Greco, Emanuela A.
    Amar, Inbal Dona
    Moretti, Antimo
    Ronzoni, Stefano
    Gimigliano, Francesca
    Vinicola, Vincenzo
    Chiacchiararelli, Fiorella
    Guadalascara, Francesco
    Pastore, Renato
    Falaschi, Paolo
    Minisola, Giovanni
    Falla, Orazio
    Castellitto, Domenico
    Lenzi, Andrea
    Villa, Paola
    Iolascon, Giovanni
    CLINICAL CASES IN MINERAL AND BONE METABOLISM, 2018, 15 (03) : 334 - 339
  • [36] The Effect of Treatment and Bone Metabolic Factors on Fracture Incidence in Patients with Thalassemia- induced Osteoporosis: An Observational Study
    Tsartsalis, Athanasios N.
    Lambrou, George, I
    Vlachou, Eugenia
    Samartzi, Athanasia
    Chrousos, George P.
    Kanaka-Gantenbein, Christina
    Kattamis, Antonis
    CURRENT DRUG THERAPY, 2020, 15 (04) : 381 - 388
  • [37] Association between Chronic Hepatitis B/C and Incidence of Osteoporosis and Bone Fractures: Results from a Retrospective Cohort Study
    Loosen, Sven H.
    Killer, Alexander
    Bock, Hans Henrich
    Luedde, Tom
    Roderburg, Christoph
    Kostev, Karel
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (20)
  • [38] Factors associated with high 24-month persistence with denosumab: results of a real-world, non-interventional study of women with postmenopausal osteoporosis inGermany, Austria, Greece, and Belgium
    Fahrleitner-Pammer, A.
    Papaioannou, N.
    Gielen, E.
    Tepie, M. Feudjo
    Toffis, C.
    Frieling, I.
    Geusens, P.
    Makras, P.
    Boschitsch, E.
    Callens, J.
    Anastasilakis, A. D.
    Niedhart, C.
    Resch, H.
    Kalouche-Khalil, L.
    Hadji, P.
    ARCHIVES OF OSTEOPOROSIS, 2017, 12 (01)
  • [39] Factors associated with high 24-month persistence with denosumab: results of a real-world, non-interventional study of women with postmenopausal osteoporosis in Germany, Austria, Greece, and Belgium
    A. Fahrleitner-Pammer
    N. Papaioannou
    E. Gielen
    M. Feudjo Tepie
    C. Toffis
    I. Frieling
    P. Geusens
    P. Makras
    E. Boschitsch
    J. Callens
    A. D. Anastasilakis
    C. Niedhart
    H. Resch
    L. Kalouche-Khalil
    P. Hadji
    Archives of Osteoporosis, 2017, 12
  • [40] Fracture incidence and changes in quality of life in women with an inadequate clinical outcome from osteoporosis therapy: the Observational Study of Severe Osteoporosis (OSSO)
    Cooper, C.
    Jakob, F.
    Chinn, C.
    Martin-Mola, E.
    Fardellone, P.
    Adami, S.
    Thalassinos, N. C.
    Melo-Gomes, J.
    Torgerson, D.
    Gibson, A.
    Marin, F.
    OSTEOPOROSIS INTERNATIONAL, 2008, 19 (04) : 493 - 501